The role of ß-amyloid in Alzheimer's disease

doi:10.1017/CBO9780511544873.032

31 - The role of ß-amyloid in Alzheimer's disease

from Part IV - Alzheimer's disease

Published online by Cambridge University Press: 04 August 2010

Anthony E. Lang and

M. Flint Beal: Affiliation:
Cornell University, New York
Anthony E. Lang: Affiliation:
University of Toronto
Albert C. Ludolph: Affiliation:
Universität Ulm, Germany
Roger M. Nitsch: Affiliation:
Division of Psychiatry Research, University of Zurich, August Forel Strasse 1, Zurich 8008, Switzerland

Book contents

Get access

Summary

Introduction

ß-Amyloid is a central element of the histopathology of Alzheimer's disease. It damages neurons and it causes the formation of neurofibrillary tangles. It is genetically linked to mutations that cause familial Alzheimer's disease, and it is associated with polymorphisms that increase the risk for developing Alzheimer's disease. ß-Amyloid can be imaged by positron emission tomography in living people, and it is a major therapeutic target for the development of disease-modifying therapies (Selkoe, 2004).

ß-amyloid plaques are major histophathological hallmarks of Alzheimer's disease

The neuropathological diagnosis of Alzheimer's disease is based upon the presence in brain of ß-amyloid plaques and neurofibrillary tangles (Duyckaerts & Dickson, 2003). ß-Amyloid deposits occur within the neuropil in several forms depending upon the degree of aggregation and fibrillization of the amyloid ß-peptides Aß40 and Aß42, their principal proteinaceous components. The two most abundant, albeit different, forms of amyloid plaques are neuritic ß-amyloid plaques and diffuse plaques. Neuritic, or “senile,” ß-amyloid plaques occur rarely in healthy subjects, they are an early histopathological sign of Alzheimer's disease (Tiraboschi et al., 2004). Neuritic ß-amyloid plaques are composed of higher-order ß-amyloid fibrils that can be detected by Thioflavin S or Congo red, as well as by silver-based stains and by immunohistochemistry. Amyloid fibrils within the cores of neuritic ß-amyloid plaques visualized by electron microscopy have diameters of upto 10 nm, and often occur in radiating, star-like assemblies.

Type: Chapter
Information: Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 452 - 458

DOI: https://doi.org/10.1017/CBO9780511544873.032 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aguzzi, A. & Haass, C. (2003). Games played by rogue proteins in prion disorders and Alzheimer's disease. Science, 302, 814–18CrossRef Google Scholar PubMed

Aisen, P. S., Mehran, M., Poole, R.et al. (2004). Clinical data on Alzhemed™ after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol. Agin., 25S2, 20 (abstract)CrossRef Google Scholar

Bard, F., Cannon, C., Barbour, R. et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–19CrossRef Google Scholar

Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L. & Arnold, S. E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol., 61, 378–84CrossRef Google Scholar PubMed

Chapman, P. F., White, G. L., Jones, M. W.et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci., 2, 271–6CrossRef Google Scholar PubMed

Delaere, P., Duyckaerts, C., He, Y., Piette, F. & Hauw, J. J. (1991). Subtypes and differential laminar distributions of beta A4 deposits in Alzheimer's disease: relationship with the intellectual status of 26 cases. Acta Neuropathol., 81, 328–35CrossRef Google Scholar PubMed

Delaere, P., He, Y., Fayet, G., Duyckaerts, C. & Hauw, J. J. (1993). Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Agin., 14, 191–4CrossRef Google Scholar PubMed

Dudal, S., Krzywkowski, P., Paquette, J. et al. (2004). , P, Gervais, F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Agin., 25, 861–71CrossRef Google Scholar PubMed

Duyckaerts, C. & Dickson, D. W. (2003). Neuropathology in Alzheimer's disease. In Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders, ed. Dickson Basel: ISN Neuropath Press. pp. 47–65

Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M. & Götz, J. (2003). Beta-amyloid induces PHF-like tau filaments in tissue culture. J. Biol. Chem., 278, 40162–8CrossRef Google Scholar PubMed

Ferrer, I., Boada Rovira, M., Sanchez Guerra, M. L., Rey, M. J. & Costa-Jussa, F. (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 14, 11–20CrossRef Google Scholar PubMed

Fox, N. C., Black, R. S., Gilman, S.et al. (2004). Effects of a-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. NeuroBiol. Agin., 25S2, 84CrossRef Google Scholar

Giasson, B. I., Lee, V. M. & Trojanowski, J. Q. (2003). Interactions of amyloidogenic proteins. Neuromolec. Med., 49–58CrossRef Google Scholar PubMed

Gilman, S., Koller, M., Black, R. S.et al. (2004). Neuropsychological, CSF, and neuropathological effects of a-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol. Agin., 25S2, 84 (abstract)CrossRef Google Scholar

Götz, J., Chen, F., Dorpe, J. & Nitsch, R. M. (2001). Abeta42 fibrils induce the formation of neurofibrillary tangles in P301L tau transgenic mice. Science, 293, 1491–5CrossRef Google Scholar

Greeve, I., Kretzschmar, D., Beyn, A. et al. (2004). Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci., 24, 3899–906CrossRef Google Scholar PubMed

Hock, C., Konietzko, U., Papassotiropoulos, A. et al. (2002). Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med., 8, 1270–5CrossRef Google Scholar PubMed

Hock, C., Konietzko, U., Streffer, J. R.et al. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38, 547–54CrossRef Google Scholar PubMed

Ingelsson, M., Fukumoto, H., Newell, K. L.et al. (2004). Early A-beta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 62, 925–31CrossRef Google Scholar

Klunk, W. E., Engler, H., Nordberg, A. et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 55, 306–19CrossRef Google Scholar PubMed

Knopman, D. S., Parisi, J. E., Salviati, A. et al. (2003). Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol., 62, 1087–95CrossRef Google Scholar PubMed

Koo, E. H. & Kopan, R. (2004). Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med., 10 Suppl:S26–33CrossRef

Lemere, C. A., Beierschmitt, A., Iglesias, M. et al. (2004). Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 165, 283–97CrossRef Google Scholar

Lewis, J., Dickson, D. W., Lin, W. L.et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487–91CrossRef Google Scholar PubMed

Lombardo, J. A., Stern, E. A., McLellan, M. E.et al. (2003). Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci., 23, 10879–83CrossRef Google Scholar PubMed

Marjaux, E., Hartmann, D. & Strooper, B. (2004). Presenilins in memory, Alzheimer's disease, and therapy. Neuron, 42(2), 189–92CrossRef Google Scholar PubMed

Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430, 631–9CrossRef Google Scholar PubMed

Mattson, M. P. & Chan, S. L. (2003). Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 34, 385–97CrossRef Google Scholar PubMed

Mohajeri, H. M., Saini, K., Schultz, J. G., Wollmer, M. A., Hock, C. & Nitsch, R. M. (2002). Passive immunization against β-amyloid peptide protects CNS neurons from increased vulnerability associated with an Alzheimer's disease-causing mutationJ. Biol. Chem., 277, 33012–17CrossRef Google Scholar PubMed

Morgan, D., Diamond, D. M., Gottschall, P. E.et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982–5CrossRef Google Scholar

Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 9, 448–52CrossRef Google Scholar PubMed

Nicoll, J. A., Yamada, M., Frackowiak, J., Mazur-Kolecka, B. & Weller, R. O. (2004). Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Agin., 25, 589–97CrossRef Google Scholar

Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science, 258, 304–7CrossRef Google Scholar PubMed

Nitsch, R. M., Deng, M., Tennis, M., Schoenfeld, D. & Growdon, J. H. (2000). The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 48, 913–183.0.CO;2-S>CrossRef Google Scholar PubMed

Oddo, S., Caccamo, A., Shepherd, J. D.et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–21CrossRef Google Scholar PubMed

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. (2004). Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321–32CrossRef Google Scholar

Ritchie, C. W., Bush, A. I., Mackinnon, A. et al. (2003). Metal–protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 60, 1685–91CrossRef Google Scholar PubMed

Rossjohn, J., Cappai, R., Feil, S. C.et al. (1999). Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol., 6(4), 327–31Google Scholar PubMed

Sano, M., Ernesto, C., Thomas, R. G.et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 336, 1216–22CrossRef Google Scholar PubMed

Schenk, D., Barbour, R., Dunn, W. et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–7CrossRef Google Scholar PubMed

Selkoe, D. J. (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med., 140, 627–38CrossRef Google Scholar PubMed

Selkoe, D. & Kopan, R. (2003). Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci., 26, 565–97CrossRef Google Scholar PubMed

Stern, E. A., Bacskai, B. J., Hickey, G. A., Attenello, F. J., Lombardo, J. A. & Hyman, B. T. (2004). Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci., 24, 4535–40CrossRef Google Scholar PubMed

Tanzi, R. E. & Bertram, L. (2001). New frontiers in Alzheimer's disease genetics. Neuron, 32, 181–4CrossRef Google Scholar PubMed

Tiraboschi, P., Hansen, L. A., Thal, L. J. & Corey-Bloom, J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 62, 1984–9CrossRef Google Scholar PubMed

Gool, W. A., Aisen, P. S. & Eikelenboom, P. (2003). Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?J. Neurol., 250, 788–92CrossRef Google Scholar PubMed

Rotz, R. C., Kohli, B. M., Bosset, J.et al. (2004). The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci., 117, 4435–48CrossRef Google Scholar

Walsh, D. M., Klyubin, I., Fadeeva, J. V.et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535–9CrossRef Google Scholar PubMed

Wilcock, D. M., Rojiani, A., Rosenthal, A. et al. (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 24, 6144–51CrossRef Google Scholar

Zandi, P. P., Anthony, J. C., Khachaturian, A. S.et al. (2004). Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol., 61, 82–8CrossRef Google Scholar